---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-050789"
form_type: "8-K"
ticker: "CSBR"
cik: "0000771856"
company_name: "CHAMPIONS ONCOLOGY, INC."
filed_at: "2024-12-11T23:59:59+00:00"
generated_at: "2026-05-29T04:55:42.605565+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Champions Oncology Q2 FY2025: Revenue $13.5M, Net Income $730K, Adj. EBITDA $1.1M

## Summary
- Q2 revenue rose 17% YoY to $13.5M; gross margin improved to 45% from 43%
- Net income of ~$730K vs. $2.0M operating loss a year ago
- Adjusted EBITDA of $1.1M, reversed from a $1.4M loss in Q2 FY2024
- Company guides FY2025 revenue growth of at least 10%-15%, citing core strength and new data platform revenue
- No debt; cash on hand ~$2.8M; data monetization highlighted as a transformative additional revenue stream

## SEC filing metadata
- accession: 0001628280-24-050789
- form_type: 8-K
- ticker: CSBR
- cik: 0000771856
- company_name: CHAMPIONS ONCOLOGY, INC.
- filed_at: 2024-12-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/771856/000162828024050789/0001628280-24-050789-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/771856/000162828024050789/csbr-20241211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-050789
- JSON: https://secwatch.observer/filing/0001628280-24-050789.json
- Plain text: https://secwatch.observer/filing/0001628280-24-050789.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.